Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.
Visit our Writing Guide or this topic page for additional help.
Timeline
July 27, 2012
BrainStorm Cell Therapeutics raises a $206,910 seed round.
Funding rounds
People
Name
Role
LinkedIn
Adrian Harel
Employee
Liat Soffer
Employee
Further reading
Title
Author
Link
Type
Date
BrainStorm Cell Therapeutics halfCway through enrolling its Phase 3 ALS study
Christine Corrado
Web
Documentaries, videos and podcasts
Title
Date
Link
BrainStorm Cell Therapeutics halfway through enrolling its Phase 3 ALS study
January 11, 2019
Brainstorm Cell Therapeutics updates on its progressive MS drug development trials
February 12, 2019
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
Brainstorm Cell Therapeutics Inc
June 15, 2021
www.prnewswire.com:443
/PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
Heather McKenzie
May 4, 2021
BioSpace
There is also a tacit acknowledgment in the industry that the ALSFRS-R (revised) scale needs to evolve.
Brainstorm Cell Therapeutics Inc
April 19, 2021
www.prnewswire.com:443
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today...
Nick Paul
March 24, 2021
FierceBiotech
BrainStorm Cell Therapeutics has presented phase 2 data on its stem cell therapy in patients with multiple sclerosis. The small, open-label clinical trial linked autologous therapy NurOwn to a 25% improvement in measures of mobility and dexterity in around 14% of patients.
Pomerantz LLP
March 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ:...
Pomerantz LLP
February 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or the "Company") (NASDAQ:...
Brandon May
November 17, 2020
BioSpace
A Phase III trial of NurOwn® (MSC-NTF cells), BrainStorm Cell Therapeutics' investigational therapy for amyotrophic lateral sclerosis, did not find a statistically significant difference between the therapy and placebo for improving scores on a revised ALS functional rating scale.
Brian Barrett
June 23, 2020
Wired
At 37, Brian Wallach was diagnosed with the fatal disease. So he tapped a lifetime of connections to give help and hope to fellow sufferers--while grappling with his own mortality.
BioSpace
June 9, 2020
BioSpace
The ALS Association and I AM ALS announced that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics, a biotechnology company, to support an amyotrophic lateral sclerosis biomarker research study.
Is a
CompanyCompany attributes
Biotechnology
Biomedical engineering
Healthcare
Stem cellLocation
New York
New York CityCrunchbase
CIK number
Place of incorporation
DelawareIRS number
208,133,057
Total funding amount (USD)
206,910
Latest funding round date
July 27, 2012
Stock symbol
BCLI
Latest funding type
Seed round
Israel
